Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression
Frontiers in Bioscience-Landmark · 2024
DOI: 10.31083/j.fbl2904138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2024. Verfasst von Maolin Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, North Sichuan Medical College, 637100 Nanchong, Sichuan, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma, Biomarkers, Tumor, Disease Progression. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cooperation Project on Scientific Research between Nanchong City and North Sichuan Medical College.
Abstract (Originalsprache)
Background
Mounting evidence indicates that complement components play a crucial role in cancer progression. Recent findings indicate that certain complement components display a significant rise in expression within esophageal squamous cell carcinoma (ESCC). However, the specific tumorigenic functions of these components remain unclear. This study focuses on investigating the expression pattern of C1r, elucidating a role for C1r in ESCC, as well as exploring underlying mechanisms controlled by C1r.
Methods
The expression of C1r in ESCC tissues, malignant epithelial cells, and its relationship with survival were analyzed using the Gene Expression Omnibus (GEO) database and tissue microarrays. Single-cell RNA sequencing (scRNA-seq) was used to study the expression of C1r in malignant epithelial cells. C1r knockdown or C1r overexpression in cultured ESCC cells were used to assess the effects of C1r on proliferation, migration, invasion, cell-matrix adhesion, apoptosis, and growth of xenografted tumors in immunocompromised (nude) mice. Western blotting was used to detect the expression of MMP-1 and MMP-10 in C1r knockdown or C1r overexpressing ESCC cells.
Results
C1r was highly expressed in ESCC tissues, malignant epithelial cells, and cultured ESCC cell lines. High C1r expression indicated a poor prognosis. Knockdown of C1r significantly suppressed the proliferation, migration, invasion, cell-matrix adhesion, and promoted apoptosis in cultured ESCC cells. Additionally, knockdown of C1r markedly inhibited tumor growth in nude mice. Overexpression of C1r had the opposite effects. C1r induced the expression of MMP-1 and MMP-10.
Conclusions
C1r is highly expressed in ESCC and promotes the progression of this tumor type. Our findings suggest that C1r may serve as a novel prognostic biomarker and therapeutic target in ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, North Sichuan Medical College, 637100 Nanchong, Sichuan, China.
- Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, 637100 Nanchong, Sichuan, China.
- Department of Pathology, North Sichuan Medical College, 637100 Nanchong, Sichuan, China.
Förderung
- Cooperation Project on Scientific Research between Nanchong City and North Sichuan Medical College
Zitieren
APA
Tang, M., Zhao, S., Ren, L., Li, Q., Li, L., Wang, C., Meng, C., Chen, Y., & Hu, W. (2024). Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2904138
Vancouver
Tang M, Zhao S, Ren L, Li Q, Li L, Wang C, et al. Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression. Frontiers in Bioscience-Landmark. 2024. doi:10.31083/j.fbl2904138
BibTeX
@article{Tang2024,
author = {Tang, Maolin and Zhao, Shisheng and Ren, Ling and Li, Qianqian and Li, Li and Wang, Chaoli and Meng, Chunmei and Chen, Yuling and Hu, Weimin},
title = {Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression},
journal = {Frontiers in Bioscience-Landmark},
year = {2024},
doi = {10.31083/j.fbl2904138}
}
EUVIMED